Biological optimal dosing of anti-neoplastic in order to maximize therapeutic efficacy and safety
| Project/Area Number |
24590656
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Ishiguro Hiroshi 京都大学, 医学(系)研究科(研究院), 准教授 (20422925)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOI Masakazu 京都大学, 大学院医学研究科, 教授 (10207516)
TERAMUKAI Satoshi 京都府立医科大学, 医学研究科, 教授 (20359798)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | Medical Oncology / Pharamcokinetics / Supportive care / 臨床腫瘍学 / 臨床薬理学 / 薬物動態 / 薬力学 / 支持療法 / 抗悪性腫瘍薬 |
|---|
| Outline of Final Research Achievements |
For anti-cancer treatment, biologically optimal dosing in addition to state of art supportive care in order to aim for best drug efficacy is very important.
We have conducted several clinical trial aiming for better management for chemotherapy-induced nausea and vomiting, molecular targeted drug-related skin rash, 5HT3-induced constipation and published them at the major scientific conference or journal.
We also conducted clinical trial to find out biologially optimal dosing for anti-anti-neoplastics, such as decetaxel, afatinib irinotecan and TS-1. We also published them at the major scientific conference or journal.
|
Report
(5 results)
Research Products
(74 results)
-
-
-
-
-
-
[Journal Article] Phase I trial of afatinib plus in Japanese patients with advanced solid tumors, including breast cancer2015
Author(s)
Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y
-
Journal Title
Cancer Chemother Pharmacol
Volume: 76(4)
Issue: 4
Pages: 739-50
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).2014
Author(s)
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamato T, Morita S, Toi M on behalf of the JBCRG-C03 Collaborative Group.
-
Journal Title
Breast Cancer Res Treat
Volume: Volume 145, Issue 1
Issue: 1
Pages: 143-53
DOI
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Journal Article] FECとAbraxaneの投与が著効した乳癌の1例2013
Author(s)
芳林 浩史, 石黒 洋, 川口 佳奈子, 矢本 真子, 西村 友美, 山田 晴美, 南村 真紀, 西尾 直子, 中村 京平, 嶋田 功太郎, 小野 一雄, 加藤 博明
-
Journal Title
癌と化学療法
Volume: 40巻5号
Pages: 627-629
Related Report
Peer Reviewed
-
-
-
-
-
[Presentation] Prevention of chemotherapy-induced nausea and vomiting by olanzapine containing antiemetic regimen without aprepitant in Japanese female patients with breast cancer2016
Author(s)
Nishimura T, Ishiguro H, Nakakimura T, Fukui Y, Maekawa K, Nio M, Yamaguchi A, Nakayama Y, Rin S, Kotake T,Yanai S, Matsumoto Y, Takada M, Takeuchi M, Suzuki E,Sato F, Toi M
Organizer
AOS 2016 Kyoto Breast Cancer Consensus Conference 2016（ＫＢＣＣＣ）International Conference
Place of Presentation
京都市国際交流会館/ウェスティン都ホテル京都
Year and Date
2016-03-03
Related Report
Int'l Joint Research
-
-
-
-
[Presentation] Pharmacogenomicspharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose escalation for Japanese breast cancer patients2015
Author(s)
Ohno S,Ishiguro H,Yamamoto Y,Takao S,Sato N,Fujisawa T,Kadoya T ,Kuroi K,Bando H,Teramura Y,Iwata H,Tanaka S,Toi M,
Organizer
SAN ANTONIO BREAST CANCER SYMPOSIUM
Place of Presentation
San Antonio, Texas
Year and Date
2015-12-08
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Determining possible cardiotoxicity risk modifiers (ACEI, beta-blockers, and G-CSF) in breast cancer patients receiving anthracycline and trastuzumab: a case-control study2013
Author(s)
Namura M, Ishiguro H, Yamagami K, Abe H, Tsuyuki S, Yamauchi A, Inamoto T, Kan N, Yoshibayashi H, Suwa H, Ichinose Y, Kato H, Shinkura N, Toi M.
Organizer
Multinational Association of Supportive Care in Cancer (MASCC)
Place of Presentation
Berlin, Germany
Related Report
-
-
-
-
[Presentation] Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study).2013
Author(s)
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.
Organizer
San Antonio Breast Cancer Symposium
Place of Presentation
San Antonio, TX, U.S.A.
Related Report
-
[Presentation] Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer.2013
Author(s)
Masuda N, Mukai H, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Ebisawa R, Uttenreuther-Fischer M, Ando Y.
Organizer
San Antonio Breast Cancer Symposium
Place of Presentation
San Antonio, TX, U.S.A.
Related Report
-
[Presentation] BOLERO-3: Everolimus Plus Trastuzumab and Vinorelbine in Asian Patients With HER2-Positive Metastatic Breast Cancer2013
Author(s)
Toi M, Masuda N, Andre F, Ishiguro H, Fasolo A, Xu B, Jerusalem G, Shen K, Wilks S, O’Regan R, Isaacs C, Zhang Y, Taran T, Yap YS
Organizer
San Antonio Breast Cancer Symposium
Place of Presentation
San Antonio, TX, U.S.A.
Related Report
-
[Presentation] Early response to neoadjuvant chemotherapy in breast cancer : MR Imaging for prediction of pCR.2013
Author(s)
Tsuda M, Takada M, Sugie T, Kanao S, Mikami Y, Ueno T, Takeuchi M, Suzuki E, Ishiguro H, Toi M.
Organizer
13th St. Gallen International Breast Cancer Conference 2013
Place of Presentation
St. Gallen, Switzerland
Related Report
-
-
[Presentation] A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER-2-Positive Metastatic Breast Cancer.2012
Author(s)
Masuda N, Ito Y, Takao S, Doihara H, Rai Y, Horiguchi J, Kohno N, Fujiwara Y, Tokuda Y, Watanabe J, Iwata H, Ishiguro H, Miyoshi Y, Matsubara M, Kashiwaba M.
Organizer
San Antonio Breast Cancer Symposium
Place of Presentation
San Antonio, TX, U.S.A.
Related Report
-
-
-
-
-
-
-
-
-
-
-
